{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:21:27Z","timestamp":1778858487918,"version":"3.51.4"},"reference-count":90,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The management of the side effects caused by the antiretroviral therapy is one of the main problems facing clinicians. The patient\u2019s tolerability and safety influence the success of the therapy. This retrospective study assesses the tolerability and impact on metabolic profiles of antiretroviral regimens containing darunavir\/ritonavir (DRV\/r) versus those containing darunavir\/cobicistat (DRV\/c), in routine clinical practice. The database of Prof. Dr Matei Bals of the National Institute of Infectious Diseases (INBI MB) was studied for the period 2017\u20132020, allowing the inclusion in the study of 462 HIV-infected patients who received the current regimen at least three months before evaluation. The following parameters were collected and analyzed: significant medical history, associated diseases, serum levels for profile evaluation: carbohydrate, lipidic, serum level of liver and pancreatic enzymes, serum markers of cardiac function, coagulation, and renal function. DRV\/c (800 mg\/150 mg, once daily) administrated in combination with other antiretroviral (ARV) in HIV-1 infected subjects proved to be better tolerated and with a lower impact on metabolic profile than DRV\/r (600 mg\/100 mg, twice daily). Patients in DRV\/r group are significantly more at risk of developing, over time, side effects and metabolic impairments than those in DRV\/c group, in all body functions studied, with statistically significant differences (p &lt; 0.05) between the two groups. Laboratory data were correlated with patient\u2019s demographic and clinical characteristics and statistically significant outcomes have been found, proving that a personalized regimen is needed to minimize the ART side effects and to maximize the success of therapy. The results of the study showed that DRV\/c, associated with other antiretroviral drugs in the regimens of Romanian HIV infected subjects, have a more favorable metabolic profile than those containing DRV\/r.<\/jats:p>","DOI":"10.3390\/biomedicines9080987","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T09:03:53Z","timestamp":1628499833000},"page":"987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir\/Ritonavir or Darunavir\/Cobicistat in Romanian HIV Infected Patients"],"prefix":"10.3390","volume":"9","author":[{"given":"Ruxandra-Cristina","family":"Marin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-6592","authenticated-orcid":false,"given":"Delia Mirela","family":"Ti\u021b","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"S\u0103ndulescu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Matei Bal\u0219\u201d National Institute of Infectious Diseases, 021105 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Streinu-Cercel","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Matei Bal\u0219\u201d National Institute of Infectious Diseases, 021105 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-1292","authenticated-orcid":false,"given":"Simona Gabriela","family":"Bung\u0103u","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"ref_1","unstructured":"(2021, March 03). Comisia Na\u021bional\u0103 de Lupta Anti-SIDA-Date Statistice (in English National Commission for the Fight against AIDS-Statistical Data). Available online: http:\/\/cnlas.ro\/com_jce\/date-statistice.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijid.2018.03.007","article-title":"HIV care in central and eastern europe: How close are we to the target?","volume":"70","author":"Gokengin","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.exger.2006.12.003","article-title":"Accelerated immune senescence and HIV-1 infection","volume":"42","author":"Appay","year":"2007","journal-title":"Exp. Gerontol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Behl, T., Rocchetti, G., Chadha, S., Zengin, G., Bungau, S., Kumar, A., Mehta, V., Uddin, M.S., Khullar, G., and Setia, D. (2021). Phytochemicals from plant foods as potential source of antiviral agents: An overview. Pharmaceuticals, 14.","DOI":"10.3390\/ph14040381"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2010.00859.x","article-title":"HIV and the body: A review of multidisciplinary management","volume":"11","author":"Rockstroh","year":"2010","journal-title":"HIV Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.18683\/germs.2019.1178","article-title":"Consensus statement on the assessment of comorbidities in people living with HIV in Romania","volume":"9","author":"Mircescu","year":"2019","journal-title":"Germs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/archinte.161.16.1962","article-title":"Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study","volume":"161","author":"Nieuwkerk","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the international AIDS society\u2013USA panel","volume":"14","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"ref_11","unstructured":"(2021, March 03). Ministerul S\u0103n\u0103t\u0103\u0163ii Institutul Na\u0163ional De Boli Infec\u0163ioase. Available online: http:\/\/cnlas.ro\/images\/doc\/30062019_rom.pdf."},{"key":"ref_12","unstructured":"(2021, March 17). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Marin, R.C., Behl, T., Negrut, N., and Bungau, S. (2021). Management of antiretroviral therapy with boosted protease inhibitors-darunavir\/ritonavir or darunavir\/cobicistat. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030313"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","article-title":"Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro","volume":"47","author":"Koh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1086\/313852","article-title":"Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors","volume":"30","author":"Acosta","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bmcl.2013.12.057","article-title":"Structure\u2013activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2\/P3 region and discovery of cobicistat (GS-9350)","volume":"24","author":"Xu","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40121-013-0013-7","article-title":"Cobicistat: A novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors","volume":"2","author":"Nathan","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jcph.290","article-title":"Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers","volume":"54","author":"Kakuda","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: Week 48 results of a phase IIIb, open-label single-arm trial","volume":"11","author":"Tashima","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"ref_26","unstructured":"(2021, February 26). World Medical Association. Available online: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"ref_27","unstructured":"(2021, March 11). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-clinical-practice-e6r2-4-step-2b_en.pdf."},{"key":"ref_28","unstructured":"(2021, March 18). Md + CALC. Available online: https:\/\/www.mdcalc.com\/mdrd-gfr-equation."},{"key":"ref_29","unstructured":"(2021, March 21). KDIGO. Available online: https:\/\/kdigo.org\/guidelines\/."},{"key":"ref_30","unstructured":"(2021, March 27). UNAIDS. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Streinu-Cercel, A., S\u0103ndulescu, O., Ceapraga, G., Manolache, D., Stoica, M.A., and Preo\u021bescu, L.L. (2016). Prevalence of osteo-renal impairment in the Romanian HIV cohort. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1397-2"},{"key":"ref_32","first-page":"102","article-title":"Hypovitaminosis D in HIV-infected patients","volume":"5","author":"Poiana","year":"2019","journal-title":"Acta Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200101260-00007","article-title":"Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre","volume":"15","author":"Mocroft","year":"2001","journal-title":"Aids"},{"key":"ref_34","unstructured":"Feingold, K.R., Anawalt, B., and Boyce, A. (2021, June 05). Diabetes in people living with HIV. 2019. [Updated 2019 August 27], Endotext Internet, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545886\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11904-018-0399-7","article-title":"Factors associated with insulin resistance in adults with HIV receiving contemporary antiretroviral therapy: A brief update","volume":"15","author":"Hulgan","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1758-5996-3-2","article-title":"Understanding diabetes in patients with HIV\/AIDS","volume":"3","author":"Kalra","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/hiv.12530","article-title":"Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia","volume":"18","author":"Bonjoch","year":"2017","journal-title":"HIV Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease","volume":"285","author":"Ridker","year":"2001","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV medications","volume":"10","author":"Margolis","year":"2014","journal-title":"J. Med. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2870647","DOI":"10.1155\/2019\/2870647","article-title":"Changes in lipid indices in HIV+ cases on HAART","volume":"2019","author":"Ji","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"ref_43","first-page":"3","article-title":"Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy","volume":"9","author":"Mallon","year":"2007","journal-title":"AIDS Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI200316261","article-title":"HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages","volume":"111","author":"Dressman","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","article-title":"Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects","volume":"14","author":"Purnell","year":"2000","journal-title":"Aids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/met.2006.0034","article-title":"Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis","volume":"5","author":"Rosenkranz","year":"2007","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Reiss","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/375886","article-title":"Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome","volume":"37","author":"Grunfeld","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","first-page":"521","article-title":"Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features","volume":"110","author":"Ion","year":"2006","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Iasi"},{"key":"ref_50","first-page":"669","article-title":"Lipodystrophy syndrome in HIV infected patients","volume":"62","author":"Uurlings","year":"2007","journal-title":"Rev. Med. Liege"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial","volume":"16","author":"Joly","year":"2002","journal-title":"Aids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwj111","article-title":"The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design and sample characteristics","volume":"163","author":"Tien","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_54","first-page":"575","article-title":"Dyslipidemia in HIV-infected individuals","volume":"14","author":"Sprinz","year":"2010","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_55","first-page":"49","article-title":"Dyslipidemia related to antiretroviral therapy","volume":"13","author":"Estrada","year":"2011","journal-title":"AIDS Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11883-015-0493-x","article-title":"Treatment of dyslipidemia in HIV","volume":"17","author":"Sekhar","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/QAD.0000000000000807","article-title":"Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients","volume":"29","author":"Duffau","year":"2015","journal-title":"Aids"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Arrive, E., Viard, J.P., Salanave, B., Dollfus, C., Matheron, S., Reliquet, V., Arezes, E., Nailler, L., Vigouroux, C., and Warszawski, J. (2018). Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206745"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11904-015-0284-6","article-title":"Risk of cardiovascular disease in an aging HIV population: Where are we now?","volume":"12","author":"Llibre","year":"2015","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjcard.2015.10.030","article-title":"Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013","volume":"117","author":"Feinstein","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014An inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(96)09424-X","article-title":"Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?","volume":"349","author":"Vallance","year":"1997","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Maggi, P., Di Biagio, A., Rusconi, S., Cicalini, S., D\u2019Abbraccio, M., d\u2019Ettorre, G., Martinelli, C., Nunnari, G., Sighinolfi, L., and Spagnuolo, V. (2017). Cardiovascular risk and dyslipidemia among persons living with HIV: A review. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2626-z"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Weber","year":"2003","journal-title":"Aids"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.ATV.0000034707.40046.02","article-title":"HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells","volume":"22","author":"Zhong","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1590\/1413-81232018245.16682017","article-title":"Risk factors for cardiovascular disease in HIV\/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paran\u00e1-Brazil","volume":"24","author":"Muller","year":"2019","journal-title":"Cienc. Saude Coletiva"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1874613601509010051","article-title":"Risk factors of cardiovascular diseases in HIV\/AIDS patients on HAART","volume":"9","author":"Nsagha","year":"2015","journal-title":"Open AIDS J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2012.01027.x","article-title":"Endothelial dysfunction, increased inflammation and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy","volume":"14","author":"Arildsen","year":"2013","journal-title":"HIV Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Sinha, A., Ma, Y., Scherzer, R., Hur, S., Li, D., Ganz, P., Deeks, S.G., and Hsue, P.Y. (2016). Role of T-Cell dysfunction, inflammation and coagulation in microvascular disease in HIV. J. Am. Heart Assoc., 5.","DOI":"10.1161\/JAHA.116.004243"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.thromres.2013.08.016","article-title":"Chronic HIV disease and activation of the coagulation system","volume":"132","author":"Baker","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mooney, S., Tracy, R., Osler, T., and Grace, C. (2015). Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher framingham and VACS risk index scores. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144312"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.imlet.2014.06.012","article-title":"Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV","volume":"162","author":"Nasi","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1097\/QAD.0000000000001441","article-title":"Basic science and pathogenesis of ageing with HIV: Potential mechanisms and biomarkers","volume":"31","author":"Lagathu","year":"2017","journal-title":"Aids"},{"key":"ref_75","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis","year":"2003","journal-title":"AIDS Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.2174\/138161205774580804","article-title":"Hepatotoxicity of antiretroviral drugs","volume":"11","author":"Abrescia","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management","volume":"44","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_78","first-page":"430","article-title":"Drug-induced liver injury in HIV patients","volume":"2","author":"Neff","year":"2006","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_79","first-page":"459","article-title":"The spectrum of pancreatic disorders in patients with the acquired immune deficiency syndrome","volume":"84","author":"Schwartz","year":"1989","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0889-8553(05)70298-3","article-title":"The pancreas in AIDS","volume":"26","author":"Cappell","year":"1997","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1572-0241.1999.01074.x","article-title":"Abnormalities of serum amylase and lipase in HIV-positive patients","volume":"94","author":"Argiris","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199208273270901","article-title":"A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS clinical trials group","volume":"327","author":"Kahn","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00126334-200202011-00005","article-title":"Long-term exposure to lifelong therapies","volume":"29","author":"Powderly","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.11599\/germs.2013.1042","article-title":"Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir\/ritonavir-containing highly active antiretroviral therapy","volume":"3","author":"Wanless","year":"2013","journal-title":"Germs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11904-011-0080-x","article-title":"Renal issues in HIV infection","volume":"8","author":"Kalayjian","year":"2011","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"c262","DOI":"10.1159\/000321646","article-title":"Renal disease associated with antiretroviral therapy in the treatment of HIV","volume":"118","author":"Cooper","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.6.3.365","article-title":"HIV-associated nephropathy: Epidemiology, pathogenesis, diagnosis and management","volume":"6","author":"Atta","year":"2008","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAD.0b013e3282f4706d","article-title":"Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease","volume":"22","author":"Kalayjian","year":"2008","journal-title":"Aids"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1086\/533468","article-title":"Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy","volume":"46","author":"Reid","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Islam, F.M., Wu, J., Jansson, J., and Wilson, D.P. (2012). Relative risk of renal disease among people living with HIV: A systematic review and meta-analysis. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-234"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/987\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:43:02Z","timestamp":1760164982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["biomedicines9080987"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9080987","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]}}}